Dr. Patrick Hwu
banner
patrickhwumd.bsky.social
Dr. Patrick Hwu
@patrickhwumd.bsky.social
Moffitt Cancer Center President and CEO Tumor immunologist. Inspired leader. Girl dad. #DocsWhoRock. Driven to save more lives from #cancer. @moffittnews.bsky.social #Immunology #ImmunoSky #Immunotherapy
🌟These findings may lead to vaccine and adoptive cell therapy strategies against pancreatic cancer.

🔗 Here's a link to the full study: lnkd.in/etf8fkf8

#Immunotherapy #PancreaticCancer #CancerResearch
May 24, 2025 at 2:14 PM
➡️ In a recent study, investigators found that tumors make mistakes (translational errors) in the production of peptides that can lead to novel shared antigens on pancreatic cancers.
May 24, 2025 at 2:14 PM
➡️ This requires the identification of target peptides, called antigens, that are present in pancreatic cancers but not in normal tissues. While this can result from tumor DNA mutations, there is still a limited number of antigens capable of being recognized by T cells.
May 24, 2025 at 2:14 PM
🌟 Since cancers increase with age, future work towards understanding the mechanisms underlying these observations may lead to new treatment strategies.

🔗 Here's a link to the full article via @nejm.org - www.nejm.org/doi/full/10....

#Immunology #Immunotherapy #CancerResearch
May 3, 2025 at 6:07 PM
➡️ Analyzing nearly 50 thousand cancer patients, @oriolpich.bsky.social et al. found that patients whose tumors were infiltrated with CHIP-mutated immune cells had a worse prognosis, possibly due to increased inhibitory myeloid cells.
May 3, 2025 at 6:07 PM
🌟 Early findings suggest this approach could improve outcomes for patients who do not respond well to current immunotherapies. Personalized TIL could be an important tool in the fight against gastrointestinal cancers!

Here’s a link to the full study- www.nature.com/articles/s41591-025-03627-5
April 1, 2025 at 7:54 PM
➡️ In this study, published in Nature Medicine, Lowery, et al. found that expanding TILs that recognize patient-specific tumor mutations can enhance the immune response against cancer. When combined with anti-PD1, the response rate was 23 percent in patients with GI cancers.
April 1, 2025 at 7:54 PM
🌟 This study suggests that inhibiting MDK could be a valuable strategy to improve immunotherapy outcomes in melanoma!

🔗 Here’s a link to the full study: www.nature.com/articles/s43018-025-00929-y

@naturecancer.bsky.social
March 29, 2025 at 1:41 PM
➡️ Targeting MDK in preclinical models restored dendritic cell function, enhanced the activation of cytotoxic T cells, and improved antitumor immune responses.
March 29, 2025 at 1:41 PM
➡️ In this study, MDK was shown to induce immune suppression by altering dendritic cell function. This impaired the ability of the immune system to effectively target and eliminate melanoma cells, allowing the tumor to progress.
March 29, 2025 at 1:41 PM
🔗 Here’s a link to the full study- www.science.org/doi/10.1126/...
March 1, 2025 at 4:31 PM
🌟 This highlights the potential importance of B cells in antitumor immune responses and may indicate that B cell activation strategies should be studied in cancer patients.
March 1, 2025 at 4:31 PM
➡️ In a recent article by Ayana Ruffin, et al. dysfunctional (double negative) B cells were found to accumulate in patients with head and neck cancer and were associated with disease progression.
March 1, 2025 at 4:31 PM
➡️ B cells, which produce antibodies, are important to prevent infections and are now being studied for their role in antitumor immune responses.
March 1, 2025 at 4:31 PM